• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

口腔鳞状细胞癌术后放疗:总治疗时间的重要性。

Postoperative radiotherapy in squamous cell carcinoma of the oral cavity: the importance of the overall treatment time.

作者信息

Langendijk J A, de Jong M A, Leemans C R, de Bree R, Smeele L E, Doornaert P, Slotman B J

机构信息

Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands.

出版信息

Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):693-700. doi: 10.1016/s0360-3016(03)00624-2.

DOI:10.1016/s0360-3016(03)00624-2
PMID:14529773
Abstract

PURPOSE

To test the hypothesis that (1) the distinction between intermediate- and high-risk patients by clustering different prognostic factors results in a significant difference in treatment outcome and (2) a shorter interval between surgery and radiotherapy and shorter overall treatment times of radiation (OTTRT) result in higher rates of locoregional control (LRC).

METHODS AND MATERIALS

Included were patients (n = 217) with previously untreated squamous cell carcinoma of the oral cavity treated with radical surgery and postoperative radiotherapy. Patients with extranodal spread or microscopic residual disease and patients with two or more other risk factors (i.e., N2b-N3, >1 nodal level involved, perineural growth, or stage T3-T4) were classified as high-risk patients. Patients with only one other risk factor were classified as intermediate risk.

RESULTS

In the intermediate-risk group, the 3-year LRC was 87% as compared with 66% in the high-risk group (p = 0.0005). No association was found between interval and LRC. However, the OTTRT was significantly associated with LRC. The 3-year LRC was 87%, 75%, 69%, and 51% when the OTT was <6 weeks, 6-7 weeks, 7-8 weeks, and >8 weeks, respectively (p = 0.0004). The 3-year overall survival (OS) in the intermediate risk patients was 74% compared with 50% in the high-risk group (p = 0.0014). A significant association was also found between the OS and OTTRT. The OS increased from 50% when the OTTRT was >8 weeks to 74% when the OTT was <6 weeks (p = 0.006). Similar results were found with regard to the disease-free survival (DFS). In the multivariate analysis, both risk group and OTT were significantly associated with LRC, DFS, and OS. No significant interaction term was present between these two factors, which means that the OTT was of importance both for the high-risk and the intermediate-risk patients.

CONCLUSION

In the subset of patients with carcinoma of the oral cavity, the classification of high- and intermediate-risk patients by clustering a number of prognostic factors provides important prognostic information regarding LRC, DFS, and OS. The OTT was the most important prognostic factor both in the high-risk and intermediate-risk patients. Reducing the OTT to 6 weeks or less is a rather simple measure to achieve a considerable improvement of the outcome of treatment in this category of patients.

摘要

目的

检验以下假设:(1)通过对不同预后因素进行聚类分析来区分中危和高危患者,会导致治疗结果出现显著差异;(2)手术与放疗之间的间隔时间较短以及放疗总治疗时间(OTTRT)较短会导致局部区域控制(LRC)率更高。

方法和材料

纳入217例先前未经治疗的口腔鳞状细胞癌患者,这些患者接受了根治性手术和术后放疗。有结外扩散或微小残留病灶的患者以及有两个或更多其他危险因素(即N2b - N3、累及一个以上淋巴结区域、神经周围浸润或T3 - T4期)的患者被分类为高危患者。仅有一个其他危险因素的患者被分类为中危患者。

结果

在中危组中,3年局部区域控制率为87%,而高危组为66%(p = 0.0005)。未发现间隔时间与局部区域控制之间存在关联。然而,放疗总治疗时间与局部区域控制显著相关。当放疗总治疗时间<6周、6 - 7周、7 - 8周和>8周时,3年局部区域控制率分别为87%、75%、69%和51%(p = 0.0004)。中危患者的3年总生存率为74%,而高危组为50%(p = 0.0014)。总生存率与放疗总治疗时间之间也发现了显著关联。当放疗总治疗时间>8周时总生存率为50%,当放疗总治疗时间<6周时增至74%(p = 0.006)。无病生存率(DFS)也得到了类似结果。在多变量分析中,风险组和放疗总治疗时间均与局部区域控制、无病生存率和总生存率显著相关。这两个因素之间不存在显著的交互项,这意味着放疗总治疗时间对高危和中危患者都很重要。

结论

在口腔癌患者亚组中,通过对多个预后因素进行聚类分析来对高危和中危患者进行分类,可提供有关局部区域控制、无病生存率和总生存率的重要预后信息。放疗总治疗时间在高危和中危患者中都是最重要的预后因素。将放疗总治疗时间缩短至6周或更短是在这类患者中实现治疗结果显著改善的一个相当简单的措施。

相似文献

1
Postoperative radiotherapy in squamous cell carcinoma of the oral cavity: the importance of the overall treatment time.口腔鳞状细胞癌术后放疗:总治疗时间的重要性。
Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):693-700. doi: 10.1016/s0360-3016(03)00624-2.
2
The importance of immunohistochemical expression of EGFr in squamous cell carcinoma of the oral cavity treated with surgery and postoperative radiotherapy.表皮生长因子受体(EGFr)免疫组化表达在接受手术及术后放疗的口腔鳞状细胞癌中的重要性。
Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1323-9. doi: 10.1016/j.ijrobp.2006.03.011. Epub 2006 Jun 5.
3
Risk-group definition by recursive partitioning analysis of patients with squamous cell head and neck carcinoma treated with surgery and postoperative radiotherapy.通过对接受手术和术后放疗的头颈部鳞状细胞癌患者进行递归划分分析来定义风险组。
Cancer. 2005 Oct 1;104(7):1408-17. doi: 10.1002/cncr.21340.
4
Identification of High-Risk Subgroups of Patients With Oral Cavity Cancer in Need of Postoperative Adjuvant Radiotherapy or Chemo-Radiotherapy.口腔癌患者中需要术后辅助放疗或放化疗的高危亚组的识别。
Medicine (Baltimore). 2016 May;95(22):e3770. doi: 10.1097/MD.0000000000003770.
5
An analysis of factors influencing the outcome of postoperative irradiation for squamous cell carcinoma of the oral cavity.口腔鳞状细胞癌术后放疗结局的影响因素分析
Int J Radiat Oncol Biol Phys. 1997 Aug 1;39(1):137-48. doi: 10.1016/s0360-3016(97)00152-1.
6
Treatment results and prognostic factors of advanced T3--4 laryngeal carcinoma: the University of California, San Francisco (UCSF) and Stanford University Hospital (SUH) experience.晚期T3-4期喉癌的治疗结果及预后因素:加利福尼亚大学旧金山分校(UCSF)和斯坦福大学医院(SUH)的经验
Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1172-80. doi: 10.1016/s0360-3016(01)01538-3.
7
Time factor in postoperative radiotherapy: a multivariate locoregional control analysis in 868 patients.术后放疗中的时间因素:868例患者的多因素局部区域控制分析
Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):399-412. doi: 10.1016/s0360-3016(02)04469-3.
8
Definitive (chemo)radiotherapy is a curative alternative for standard of care in advanced stage squamous cell carcinoma of the oral cavity.根治性(放化疗)是晚期口腔鳞状细胞癌标准治疗的一种有治愈可能的替代选择。
Oral Oncol. 2017 Dec;75:163-168. doi: 10.1016/j.oraloncology.2017.11.006.
9
Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma.治疗前 18F-FDG PET/CT 最大标准化摄取值对局部晚期头颈部鳞状细胞癌的预后价值。
Clin Transl Oncol. 2017 Nov;19(11):1337-1349. doi: 10.1007/s12094-017-1674-6. Epub 2017 May 24.
10
Long term results of postoperative Intensity-Modulated Radiation Therapy (IMRT) in the treatment of Squamous Cell Carcinoma (SCC) located in the oropharynx or oral cavity.术后调强放射治疗(IMRT)用于治疗口咽或口腔鳞状细胞癌(SCC)的长期结果。
Radiat Oncol. 2015 Dec 4;10:251. doi: 10.1186/s13014-015-0561-y.

引用本文的文献

1
Impact of postoperative fluorodeoxyglucose positron emission tomography/computed tomography on adjuvant head and neck cancer treatment.术后氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描对辅助性头颈癌治疗的影响
JNCI Cancer Spectr. 2025 Jul 1;9(4). doi: 10.1093/jncics/pkaf077.
2
Delayed Postoperative Radiotherapy in Head & Neck Cancers-A Systematic Review and Meta-Analysis.头颈部癌症术后延迟放疗的系统评价与Meta分析
Laryngoscope. 2025 May;135(5):1563-1570. doi: 10.1002/lary.31990. Epub 2025 Jan 2.
3
Association of Patient and Tumor Characteristics With Outcomes in Young Head and Neck Squamous Cell Carcinoma Patients.
年轻头颈鳞状细胞癌患者的患者及肿瘤特征与预后的相关性
Clin Otolaryngol. 2025 Jan;50(1):15-21. doi: 10.1111/coa.14215. Epub 2024 Aug 22.
4
The Association of Ethnicity and Oncologic Outcomes for Oral Cavity Squamous Cell Carcinoma (OSCC).口腔鳞状细胞癌(OSCC)的种族与肿瘤学结局关联研究
Cancers (Basel). 2024 May 31;16(11):2117. doi: 10.3390/cancers16112117.
5
Discharge Disposition After Head and Neck Reconstruction: Effect on Adjuvant Therapy and Outcomes.头颈部重建术后的出院处置:对辅助治疗和结局的影响。
Laryngoscope. 2023 Nov;133(11):2977-2983. doi: 10.1002/lary.30648. Epub 2023 Mar 10.
6
Advances in Image-Guided Radiotherapy in the Treatment of Oral Cavity Cancer.口腔癌影像引导放射治疗的进展
Cancers (Basel). 2022 Sep 23;14(19):4630. doi: 10.3390/cancers14194630.
7
Germline genetic biomarkers to stratify patients for personalized radiation treatment.胚系遗传生物标志物用于对患者进行个体化放射治疗分层。
J Transl Med. 2022 Aug 12;20(1):360. doi: 10.1186/s12967-022-03561-x.
8
Survival-Weighted Health Profiles in Patients Treated for Advanced Oral Cavity Squamous Cell Carcinoma.晚期口腔鳞状细胞癌患者的生存加权健康概况
Front Oncol. 2021 Sep 29;11:754412. doi: 10.3389/fonc.2021.754412. eCollection 2021.
9
Perineural invasion/lymphovascular invasion double positive predicts distant metastasis and poor survival in T3-4 oral squamous cell carcinoma.神经周围侵犯/脉管侵犯双阳性预测 T3-4 期口腔鳞状细胞癌的远处转移和不良生存。
Sci Rep. 2021 Oct 5;11(1):19770. doi: 10.1038/s41598-021-99280-2.
10
Opioid use in patients undergoing treatment for oral cavity cancer.口腔癌患者治疗过程中的阿片类药物使用情况。
J Pain Manag. 2020;13(2):167-173.